不推荐百泌达与胰岛素合用。
百泌达是FDA批准的治疗2型糖尿病的首个GLP- 1受体激动剂药物。
BYETTA is the first FDA-approved GLP-1 receptor agonist for the treatment of type 2 diabetes.
BYDUREON和百泌达(BYETTA)都属于胰高血糖素样肽(GLP - 1)受体激动剂类药物。
BYDUREON and BYETTA belong to the glucagon-like peptide-1 (GLP-1) receptor agonist class of medications.
FDA在分别对礼来公司和Amylin公司的通报中指出，2009年6月在华盛顿举行的一次医学会议上，其公司代表夸大了百泌达有助于患者减轻体重的作用。
The FDA wrote in a separate letter to Lilly and Amylin that, at a medical meeting in Washington in June 2009, company representatives had overstated the ability of Byetta to help patients lose weight.
FDA在分别对礼来公司和Amylin公司的通报中指出，2009年6月在华盛顿举行的一次医学会议上，其公司代表夸大了百泌达有助于患者减轻体重的作用。
The FDA wrote in a separate letter to Lilly and Amylin that, at a medical meeting in Washington in June 2009, company representatives had overstated the ability of Byetta to help patients lose weight.
应用推荐